Hispanic-Latino Race is Associated with Worse Heart Failure Symptoms in Patients with Hypertrophic Cardiomyopathy

Reshma Golamari1, Alexander Khodak1, Steven D Hartman2

  • 1Columbia University Irving Medical Center, Division of Cardiology, Mount Sinai Heart Institute, Miami Beach, FL 33140, USA.

Insights

Hispanic-Latino patients with hypertrophic cardiomyopathy (HCM) experience worse heart failure symptoms. This severity is independent of other cardiovascular conditions, highlighting unique challenges for this population.

Area of Science:

  • Cardiology
  • Genetics
  • Public Health

Background:

  • Limited data exists on racial disparities in hypertrophic cardiomyopathy (HCM).
  • Hypothesized that race (Hispanic-Latino, Non-Hispanic, African-American) influences HCM clinical presentation.

Purpose of the Study:

  • To investigate the impact of race on the clinical characteristics and outcomes of patients with hypertrophic cardiomyopathy.
  • To identify potential racial differences in HCM presentation and severity.

Main Methods:

  • Retrospective analysis of 641 HCM patients (2005-2021).
  • Compared clinical characteristics, echocardiographic indices, and outcomes across Hispanic-Latino (HL), Non-Hispanic (NH), and African-American (AA) groups.
  • Utilized ANOVA, Kruskal-Wallis, and multivariate linear regression with post-hoc analyses.

Main Results:

  • HL and NH patients were older than AA patients (p < 0.001).
  • HL group had higher prevalence of females (62% vs 47%, p = 0.002) and moderate-severe mitral regurgitation (p < 0.001).
  • HL ethnicity was independently associated with worse NYHA class (p < 0.001).

Conclusions:

  • Hispanic-Latino patients with HCM exhibit more severe heart failure symptoms compared to NH and AA patients.
  • Severity of heart failure symptoms in HL patients is independent of cardiovascular comorbidities.
  • Findings underscore the need for race-specific considerations in HCM management.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
363
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
324
Increased pulse rate01:17

Increased pulse rate

Tachycardia is a condition marked by an abnormally fast or irregular heart rate, surpassing the typical resting rate. In adults, tachycardia is characterized by a pulse rate ranging from 100 to 180 beats per minute. The increased heart rate can result in inadequate blood flow to various body parts, ultimately diminishing the oxygen supply to organs and tissues.
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
635
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
306